IonMed Receives CE Mark Clearance For Bioweld1™ Tech

October 21, 2014 | IonMed announced that it has received CE Mark clearance for its Bioweld1™ cold plasma system for surgical incision closure. Bioweld1 is the first system in the emerging field of plasma medicine that was designed for use in operating rooms as a viable alternative to surgical staples, sutures and sealants. “With the CE Mark clearance of Bioweld1, our first system, we have achieved important validation for our technology, a key milestone for the company, and a significant step towards commercialization,” said Shai Levanon, CEO of IonMed. IonMed is based in Yokneam, Israel and develops and commercializes non-thermal plasma technology to enhance surgical wound closure and healing.